On November 20, 2012, the FDA released its own version of the Sylmar facility inspection report, revealing numerous concerns regarding the design, production, and quality control of the manufacturing process of Durata leads. On this news, St. Jude’s stock price fell $4.34 per share to close at $31.37 per share on November 21, 2012.

About Lieff Cabraser

Lieff Cabraser is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

Since 2003, the National Law Journal has selected Lieff Cabraser as one of the top plaintiffs’ law firms in the nation. Lieff Cabraser is one of only two plaintiffs’ law firms in the United States to receive this honor for the last ten consecutive years.

For more information about Lieff Cabraser and the firm’s representation of investors, please visit http://www.lieffcabraser.com.

Copyright Business Wire 2010

If you liked this article you might like

Can Abbott Outperform Despite Alere?

Abbott Shares Dip on Mixed Fourth-Quarter Earnings

Abbott Labs: Diagnosing Growth in 2017

Abbott Laboratories Can Merge With St. Jude Medical: FTC

FTC Allows Abbott to Spin Off Units, Buy St. Jude Medical